Impact of metal coordination on cytotoxicity of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (Triapine) and novel insights into terminal dimethylation

Journal of Medicinal Chemistry

Volumn 52, Issue 16, 2009, Pages 5032-5043

  Kowol, Christian R ^a   Trondl, Robert ^a   Heffeter, Petra ^b   Arion, Vladimir B ^a   Jakupec, Michael A ^a   Roller, Alexander ^a   Galanski, Markus ^a   Berger, Walter ^b   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETYLPYRIDINE THIOSEMICARBAZONE; 2 PYRIDINEFORMAMIDE THIOSEMICARBAZONE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 3 AMINOPYRIDINE 2 CARBOXALDEHYDE N4 DIMETHYLTHIOSEMICARBAZONE; BIS(2 ACETYLPYRIDINETHIOSEMICARBAZONATO) N,N,S GALLIUM NITRATE; BIS(2 ACETYLPYRIDINETHIOSEMICARBAZONATO) N,N,S IRON NITRATE; BIS(2 FORMYLPYRIDINE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S GALLIUM HEXAFLUOROPHOSPHATE; BIS(2 FORMYLPYRIDINE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S IRON HEXAFLUOROPHOSPHATE; BIS(2 FORMYLPYRIDINETHIOSEMICARBAZONATO) N,N,S GALLIUM NITRATE; BIS(2 FORMYLPYRIDINETHIOSEMICARBAZONATO) N,N,S IRON NITRATE; BIS(2 PYRIDINEFORMAMIDE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S GALLIUM NITRATE; BIS(2 PYRIDINEFORMAMIDE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S IRON NITRATE; BIS(2 PYRIDINEFORMAMIDE THIOSEMICARBAZONATO) N,N,S GALLIUM NITRATE; BIS(2 PYRIDINEFORMAMIDETHIOSEMICARBAZONATO) N,N,S IRON NITRATE; BIS(3 AMINOPYRIDINE 2 CARBOXALDEHYDE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S GALLIUM HEXAFLUOROPHOSPHATE; BIS(3 AMINOPYRIDINE 2 CARBOXALDEHYDE N4 DIMETHYLTHIOSEMICARBAZONATO) N,N,S IRON NITRATE; BIS(3 AMINOPYRIDINE 2 CARBOXALDEHYDETHIOSEMICARBAZONATO) N,N,S GALLIUM NITRATE; BIS(3 AMINOPYRIDINE 2 CARBOXALDEHYDETHIOSEMICARBAZONATO) N,N,S IRON NITRATE; CYTIDINE; GALLIUM COMPLEX; IRON COMPLEX; METAL COMPLEX; PICOLINALDEHYDE THIOSEMICARBAZONE; RIBONUCLEOTIDE REDUCTASE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPLEX FORMATION; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; CYTOPATHOGENIC EFFECT; DNA METHYLATION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; MITOSIS INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TECHNIQUE; ULTRAVIOLET SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CHELATING AGENTS; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROCHEMISTRY; GALLIUM; HUMANS; IRON; OXIDATION-REDUCTION; PYRIDINES; RIBONUCLEOTIDE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES;

EID: 69149094267     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900528d     Document Type: Article

References (57)

1. Casas, J. S.; Garcia-Tasende, M. S.; Sordo, J. Main group metal complexes of semicarbazones and thiosemicarbazones. A structural review. Coord. Chem. Rev. 2000, 209, 197-261.
2. Lobana, T. S.; Rekha; Butcher, R. J.; Castineiras, A.; Bermejo, E.; Bharatam, P. V. Bonding trends of thiosemicarbazones in mononuclear and dinuclear copper(I) complexes: syntheses, structures, and theoretical aspects. Inorg. Chem. 2006, 45, 1535-1542.
3. Barbazan, P.; Carballo, R.; Casas, J. S.; Garcia-Martinez, E.; Pereiras-Gabian, G.; Sanchez, A.; Vazquez-Lopez, E. M. Synthesis and characterization of new trimeric rhenium(I) complexes. The influence of steric factors on the size of pyrazolonaterhenium(I) metallomacrocycles. Inorg. Chem. 2006, 45, 7323-7330.
4. Pedrido, R.; Romero, M. J.; Bermejo, M. R.; Gonzalez-Noya, A. M.; Garcia-Lema, I.; Zaragoza, G. Metal-catalyzed oxidation processes in thiosemicarbazones: new complexes with the ligand N-{2-([4-N-ethylthiosemicarbazone]-methyl)phenyl}-p-toluenesulfonamide. Chem. - Eur. J. 2008, 14, 500-512.
5. West, D. X.; Padhye, S. B.; Sonawane, P. B. Structural and physical correlations in the biological properties of transition metal heterocyclic thiosemicarbazone and S-alkyl dithiocarbazate complexes. Struct. Bonding (Berlin) 1991, 76, 1-50.
6. 64Cu- complexes for the positron emission tomography imaging of hypoxia. J. Med. Chem. 2008, 51, 2985-2991.
7. Brockman, R. W.; Thomson, J. R.; Bell, M. J.; Skipper, H. E. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res. 1956, 16, 167-170.
8. French, F. A.; Blanz, E. J., Jr. The carcinostatic activity of thiosemicarbazones of formyl heteroaromatic compounds. III. Primary correlation. J. Med. Chem. 1966, 9, 585-589.
9. DeConti, R. C.; Toftness, B. R.; Agrawal, K. C.; Tomchick, R.; Mead, J. A. R.; Bertino, J. R.; Sartorelli, A. C.; Creasey, W. A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. 1972, 32, 1455-1462.
10. Krakoff, I. H.; Etcubanas, E.; Tan, C.; Mayer, K.; Bethune, V.; Burchenal, J. H. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its iron-chelating properties. Cancer Chemother. Rep. 1974, 58, 207-212.
11. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006, 12, 6876-6883.
12. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T. C.; Zee, B.; Mok, T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest. New Drugs 2008, 26, 169-173.
13. Karp, J. E.; Giles, F. J.; Gojo, I.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res. 2008, 32, 71-77.
14. Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond, G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Invest. New Drugs 2007, 25, 553-558.
15. Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E. A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest. New Drugs 2007, 25, 471-477.
16. Moore, E. C.; Zedeck, M. S.; Agrawal, K. C.; Sartorelli, A. C. Inhibition of ribonucleoside diphosphate reductase by 1-formylisoquinoline thiosemicarbazone and related compounds. Biochemistry 1970, 9, 4492-4498.
17. French, F. A.; Blanz, E. J., Jr.; Shaddix, S. C.; Brockman, R. W. α-(N)-Formylheteroaromatic thiosemicarbazones. Inhibition of tumor-derived ribunucleoside diphosphate reductase and correlation with in vivo antitumor activity. J. Med. Chem. 1974, 17, 172-181.
18. Moore, E. C.; Sartorelli, A. C. Inhibition of ribonucleotide reductase by α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Pharmacol. Ther. 1984, 24, 439-447.
19. Liu, M.-C.; Lin, T.-S.; Sartorelli, A. C. Chemical and biological properties of cytotoxic α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 1995, 32, 1-35.
20. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 2006, 6, 409-431.
21. Kolberg, M.; Strand, K. R.; Graff, P.; Andersson, K. K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 2004, 1699, 1-34.
22. Tanaka, H.; Arakawa, H.; Yamaguchi, T.; Shlralsh, K.; Fukuda, S.; Matsui, K.; Take, Y.; Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000, 404, 42-49.
23. Nakano, K.; Balint, E.; Ashcroft, M.; Vousden, K. H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000, 19, 4283-4289.
24. Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec,M. A.; Schmidt, P. P.; Arion, V. B.; Keppler, B. K. Gallium(III) and iron(III) complexes of α-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J. Med. Chem. 2007, 50, 1254-1265.
25. Shao, J.; Zhou, B.; Di Bilio, A. J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y. A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther. 2006, 5, 586-592.
26. Finch, R. A.; Liu, M.-C.; Cory, A. H.; Cory, J. G.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP). An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul. 1999, 39, 3-12.
27. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
28. Wang, Y.; Liu, M.-C.; Lin, T.-S.; Sartorelli, A. C. Synthesis and antitumor activity of 3- and 5-hydroxy-4-methylpyridine-2-carboxaldehyde thiosemicarbazones. J. Med. Chem. 1992, 35, 3667-3671.
29. Niu, C.; Li, J.; Doyle, T. W.; Chen, S.-H. Synthesis of 3-amino-2-pyridinecarboxaldehyde thiosemicarbazone (3-AP). Tetrahedron 1998, 54, 6311-6318.
30. Li, J.; Zheng, L.-M.; King, I.; Doyle, T. W.; Chen, S.-H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarbazone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr. Med. Chem. 2001, 8, 121-133.
31. Kelly, T. A.; McNeil, D. W. A simple method for the protection of aryl amines as their t-butylcarbamoyl (Boc) derivatives. Tetrahedron Lett. 1994, 35, 9003-9006.
32. Venuti, M. C.; Stephenson, R. A.; Alvarez, R.; Bruno, J. J.; Strosberg, A. M. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogs of 1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazoline. J. Med. Chem. 1988, 31, 2136-2145.
33. 4] derived from 2-acetylpyridine-N(4),N(4)-(butane-1,4-diyl) thiosemicarbazone (HPranthas). J. Mol. Struct. 2005, 737, 61-67.
34. Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion, V. B.; Keppler, B. K. Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. J. Inorg. Biochem. 2007, 101, 1946-1957.
35. Pessoa, M. M. B.; Andrade, G. F. S.; Paoli Monteiro, V. R.; Temperini, M. L. A. 2-Formylpyridinethiosemicarbazone and methyl derivatives: spectroscopic studies. Polyhedron 2001, 20, 3133-3141.
36. Bermejo, E.; Castifieiras, A.; Fostiak, L. M.; Garcia, I.; Llamas-Saiz, A. L.; Swearingen, J. K.; West, D. X. Synthesis; characterization and molecular structure of 2-pyridylformamide N(4)-dimethylthiosemicarbazone and some five-coordinated zinc(II) and cadmium(II) complexes. Z. Naturforsch., B: Chem. Sci. 2001, 56, 1297-1305.
37. West, D. X.; Bain, G. A.; Butcher, R. J.; Jasinski, J. P.; Li, Y.; Pozdniakiv, R. Y. Structural studies of three isomeric forms of heterocyclic N(4)-substituted thiosemicarbazones and two nickel-(II) complexes. Polyhedron 1996, 15, 665-674.
38. Odenike, O. M.; Larson, R. A.; Gajria, D.; Dolan, M. E.; Delaney, S. M.; Karrison, T. G.; Ratain, M. J.; Stock, W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest. New Drugs 2008, 26, 233-239.
39. CRC Handbook of Chemistry and Physics; Lide, D. R., Ed.; CRC Press: Boca Raton, FL, 2004.
40. Kowol, C. R.; Reisner, E.; Chiorescu, I.; Arion, V. B.; Galanski, M.; Deubel, D. V.; Keppler, B. K. An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox non-innocent α-N-heterocyclic chalcogensemicarbazones. Inorg. Chem. 2008, 47, 11032-11047.
41. Richardson, D. R.; Kalinowski, D. S.; Richardson, V.; Sharpe, P. C.; Lovejoy, D. B.; Islam, M.; Bernhardt, P. V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J. Med. Chem. 2009, 52, 1459-1470.
42. Easmon, J.; Heinisch, G.; Hofmann, J.; Langer, T.; Grunicke, H. H.; Fink, J.; Purstinger, G. Thiazolyl and benzothiazolyl hydrazones derived from α-(N)-acetylpyridines and diazines: synthesis, antiproliferative activity and CoMFA studies. Eur. J. Med. Chem. 1997, 32, 397-408.
43. West, D. X.; Swearingen, J. K.; Valdes-Martinez, J.; Hernandez-Ortega, S.; El-Sawaf, A. K.; Van Meurs, F.; Castineiras, A.; Garcia, I.; Bermejo, E. Spectral and structural studies of iron(III), cobalt(II,III) and nickel(II) complexes of 2-pyridineformamide N(4)-methylthiosemicarbazone. Polyhedron 1999, 18, 2919-2929.
44. Mendes, I. C.; Soares, M. A.; dos Santos, R. G.; Pinheiro, C.; Beraldo, H. Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: cytotoxic activity against malignant glioblastoma. Eur. J. Med. Chem. 2009, 44, 1870-1877.
45. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104, 1450-1458.
46. Easmon, J.; Heinisch, G.; Holzer, W.; Rosenwirth, B. Novel thiosemicarbazones derived from formyl- and acyldiazines: synthesis, effects on cell proliferation, and synergism with antiviral agents. J. Med. Chem. 1992, 35, 3288-3296.
47. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49, 6510-6521.
48. Agrawal, K. C.; Lee, M. H.; Booth, B. A.; Moore, E. C.; Sartorelli, A. C. Potential antitumor agents. 11. Inhibitors of alkaline phosphatase, an enzyme involved in the resistance of neoplastic cells to 6-thiopurines. J. Med. Chem. 1974, 17, 934-938.
49. McElhinney,R. S. Derivatives of thiocarbamic acid. I. Preparation of 4-substituted thiosemicarbazides. J. Chem. Soc. 1966, 10, 950-955.
50. Castineiras, A.; Garcia, I.; Bermejo, E.; West, D. X. Structural and spectral studies of 2-pyridineformamide thiosemicarbazone and its complexes prepared with zinc halides. Z. Naturforsch., B: Chem. Sci. 2000, 55, 511-518.
51. Barette, W. C., Jr.; Johnson, H. W., Jr.; Sawyer, D. T. Voltammetric evaluation of the effective acidities (pKa′) for Broensted acids in aprotic solvents. Anal. Chem. 1984, 56, 1890-1898.
52. Sheldrick, G. M. SHELXS-97, Program for Crystal Structure Solution; University Gottingen: Gottingen, Germany, 1997.
53. Sheldrick, G. M. SHELXL-97, Program for Crystal Structure Refinement; University Gottingen: Gottingen, Germany, 1997.
54. Johnson, G. K. Report ORNL-5138; Oak Ridge National Laboratory; Oak Ridge, TN, 1976.
55. International Tables for X-ray Crystallography; Kluwer Academic Press: Dodrecht, The Netherlands, 1992; Vol. C, Tables 4.2.6.8 and 6.1.1.4.
56. Heffeter, P.; Jakupec, M. A.; Korner, W.; Wild, S.; von Keyserlingk, N. G.; Elbling, L.; Zorbas, H.; Korynevska, A.; Knasmuller, S.; Sutterluty, H.; Micksche, M.; Keppler, B. K.; Berger, W. Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem. Pharmacol. 2006, 71, 426-440.
57. Szekeres, T.; Gharehbaghi, K.; Fritzer, M.; Woody, M.; Srivastava, A.; van't Riet, B.; Jayaram, H. N.; Elford, H. L. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 1994, 34, 63-66.